AstraZeneca shares fell on September 11 following disappointing clinical results. The company’s breast cancer drug, Etcamah (camizestrant), failed to meet its primary goal in the late-stage SERENA-4 trial.
The study evaluated Etcamah combined with Pfizer’s Ibrance (palbociclib). Researchers tested the combination as a first-line treatment for HR-positive, HER2-negative advanced breast cancer.
The trial showed no statistically significant improvement in progression-free survival compared to standard care. This outcome stalls AstraZeneca’s efforts to market the drug to a broader population of newly diagnosed patients.
AstraZeneca’s U.S.-listed shares declined 3% in after-hours trading. Etcamah currently holds accelerated FDA approval for a smaller patient group with a specific gene mutation.